Golidocitinib Combined With Selinexor for CAEBVD — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Golidocitinib Combined With Selinexor for CAEBVD — Stella

Home/Lymphohistiocytosis/

View on ClinicalTrials.gov

Recruiting

Back to Lymphohistiocytosis trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Beijing Friendship Hospital, Beijing

Key details

Phase

Safety & dosing / Large-scale testing

Sponsor

Beijing Friendship Hospital

Enrollment target

~28 participants

Started

January 2026

Primary completion

January 2027

Age range

18 Years – 70 Years

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.